Incidence and Outcomes of Patients With Mismatch Repair Deficient Rectal Cancer Operated in 2016: A Nationwide Cohort From The Netherlands
Clinical Colorectal Cancer · 2025
DOI: 10.1016/j.clcc.2024.12.003 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Colorectal Cancer, 2025. Verfasst von Eline G M van Geffen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Treatment and Quality of Life and Imaging and…. Hauptthemen laut MEDLINE: Rectal Neoplasms, DNA Mismatch Repair, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society.
Abstract (Originalsprache)
INTRODUCTION: Data regarding the incidence and outcomes of mismatch repair deficient (dMMR) rectal cancer is limited. This study characterizes dMMR rectal cancer patients, comparing response after neoadjuvant radiotherapy and oncological outcomes to mismatch repair proficient (pMMR) rectal cancer patients. METHOD: A retrospective cross-sectional cohort study was conducted in 67 Dutch centers. Data including patient and tumor characteristics, radiological and pathological reports and oncological follow-up outcomes were gathered from documentation in electronic patient files for patients who underwent a curative resection for primary rectal cancer in 2016. MMR-status was verified in pathology reports from immunohistochemistry or PCR microsatellite instability testing. RESULTS: MMR-status was determined in 1645 (54.9%) of 3001 stage I-IV rectal cancer patients, of which 46 (2.8%) were dMMR. Median follow up was 50 months (IQR 38-55). MMR-status was determined more often in younger patients. DMMR tumors were more locally advanced (cT4 23.9% vs. 8.8%, P = .010), and more distally located (mean distance to anorectal junction 3.6 cm vs. 5.3 cm, P = .004) than pMMR tumors. While radiological response after neoadjuvant (chemo)radiotherapy was similar, pathological complete response was significantly higher in dMMR compared to pMMR tumors (24.0% vs. 10.0%, P = .039). Four-year local recurrence, distant metastases, cancer-specific or overall survival rate between patients with dMMR or pMMR tumors were similar. CONCLUSION: In this population-based cohort, 2.8% of rectal cancers in which MMR-status was determined were subtyped as dMMR. Surprisingly, dMMR was associated with higher pathological complete response rate to neoadjuvant (chemo) radiotherapy than pMMR. MMR-status did not impact oncological outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Treatment and Quality of Life and Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.
- Department of Surgery, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands.
- Treatment and Quality of Life and Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands; Department of Pathology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Pathology, Netherlands Cancer Institute Amsterdam, The Netherlands.
- Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; GROW School of Oncology and Developmental Biology, University of Maastricht, Maastricht, The Netherlands.
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Förderung
- Dutch Cancer Society
Zitieren
APA
van Geffen, E. G. M., Hogewoning, C. R. C., Hazen, S. J. A., Sluckin, T. C., Lange, M. M., Snaebjornsson, P., Beets-Tan, R. G. H., Marijnen, C. A. M., Verhoef, C., Chalabi, M., Tanis, P. J., Kusters, M., Aukema, T. S., & behalf of the Dutch Snapshot Research Group (2025). Incidence and Outcomes of Patients With Mismatch Repair Deficient Rectal Cancer Operated in 2016: A Nationwide Cohort From The Netherlands. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.12.003
Vancouver
van Geffen EGM, Hogewoning CRC, Hazen SJA, Sluckin TC, Lange MM, Snaebjornsson P, et al. Incidence and Outcomes of Patients With Mismatch Repair Deficient Rectal Cancer Operated in 2016: A Nationwide Cohort From The Netherlands. Clinical Colorectal Cancer. 2025. doi:10.1016/j.clcc.2024.12.003
BibTeX
@article{vanGeffen2025,
author = {van Geffen, Eline G M and Hogewoning, Cornelis R C and Hazen, Sanne-Marije J A and Sluckin, Tania C and Lange, Marilyne M and Snaebjornsson, Petur and Beets-Tan, Regina G H and Marijnen, Corrie A M and Verhoef, Cornelis and Chalabi, Myriam and Tanis, Pieter J and Kusters, Miranda and Aukema, Tjeerd S and behalf of the Dutch Snapshot Research Group, behalf of the Dutch Snapshot Research Group},
title = {Incidence and Outcomes of Patients With Mismatch Repair Deficient Rectal Cancer Operated in 2016: A Nationwide Cohort From The Netherlands},
journal = {Clinical Colorectal Cancer},
year = {2025},
doi = {10.1016/j.clcc.2024.12.003}
}
EUVIMED